In this week’s Homerun Slides, a closer look at the workings and efficacy of DPP-4 inhibitors… To download the complete set in PowerPoint format, just use this link: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 8 Catch up on past …
Read More »Increase in Osteoporosis Thought Due to Increase in DPP-4
Postmenopausal women with normal glucose tolerance focus of study.
Read More »Phase II Trials for Omarigliptin Prove Hopeful for Phase III Trials
Research was recently published inDiabetes Care as a Phase II study to determine optimal dosing, tolerability and efficacy of a new, once-weekly DPP-4 inhibitor called omarigliptin. Over 12 weeks, the researchers looked at HbA1C, 2-hour postprandial glucose and fasting glucose. Currently, the DPP-4 inhibitors on the market are all once-daily. …
Read More »Safety and Efficacy of Vildagliptin and Sitagliptin in Renally Impaired Type 2 Diabetics
Dipeptidyl peptidase-4 (DPP4) inhibitors are generally well-tolerated for use in patients with severe renal impairment...
Read More »FDA Warns DPP-4 Inhibitors Could Cause Severe and Disabling Joint Pain
Risk warning, precaution added to labels of all drugs in this class… FDA warned recently that DPP-4 inhibitors could cause severe and disabling joint pain. The agency has added a new warning and precaution about this risk to the labels of all drugs in this class. If patients experience …
Read More »The Effectiveness of Combination Treatment with Insulin and Sitagliptin in T2 Patients
Patients on therapy may see increased reduction in HbA1c, lower BP, lower lipid values…. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used for the treatment of type 2 diabetes. Sitagliptin was the first medication approved for people with type 2 diabetes who are taking insulin. There are not a lot of …
Read More »The Outcome of DPP-4 Inhibitors in Type 2 Patients on Hemodialysis
Decreased chance of hypoglycemic event and greater safety profile shown in use of this therapy… Diabetes is the main reason for renal failure in today’s population. Currently, the main treatment option for a hemodialysis diabetic patient is insulin therapy. Insulin therapy is a difficult regimen for many patients due to …
Read More »DPP-4 Inhibitors and Type 2 Elderly Patients
In a study, older patients taking Januvia reduced their A1c’s without an increased risk of hypoglycemia…. The mortality rate for elderly individuals with type 2 diabetes is twice that of elderly individuals without type 2 diabetes. That is why it is very important for elderly individuals with diabetes to optimize …
Read More »TECOS Trial: No CVD Risks or Heart Failure with Sitagliptin in High-Risk Diabetic Patients
No significant difference in incidence of infections, cancer, renal failure, or severe hypoglycemia… In patients with type 2 diabetes and cardiovascular disease, the use of sitagliptin (Januvia, Merck), a dipeptidyl peptidase-4 (DPP-4) inhibitor used to lower HbA1c levels, is not associated with an increased risk of cardiovascular events, according to …
Read More »FDA Panel Recommends New CV Safety Warnings on Onglyza and Nesina DPP-4s
Updated label information recommendation is in light of completed cardiovascular-outcomes studies.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.